Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

Even when equities are volatile, investors can find great stocks to buy. And the rules for investing in the current ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...

The S&P 500, the Dow Jones, and the NASDAQ all moved between 0.8% and 1% lower by mid-afternoon. Palantir (PLTR) stock ...

Merck & Co.‘s planned debut this fall of an injectable form of its breakthrough cancer treatment Keytruda will simplify care, ...

Merck is expanding domestic manufacturing with a $895 million investment in its Kansas factory, one of several major projects ...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Despite the rosy long-term prospects, short-term headwinds such as COVID ...

The report runs an in-depth analysis of market trends, key players, and future opportunities. The generic drugs market ...

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck ...

Concerns over long-term growth, especially after Keytruda’s exclusivity ends in 2028, have weighed on the stock. While Merck is working to offset this loss with new drug launches, like a ...